Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbisko CaymanFRA:8ZD -0.84%55 PS Ratio is 10.17 as of Aug. 15, 2026, which is 60% below its 10-year median of 25.38. GuruFocus rates FRA:8ZD with a GF Score™ of 55/100 and a GF Value™ of €1.38 (Fairly Valued). The stock has 6 warning signs investors should review. Among 931 Biotechnology companies, Abbisko Cayman ranks worse than 51.24% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Abbisko Cayman's share price is €1.18.
Abbisko Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.12. Hence, Abbisko Cayman's PS Ratio for today is 10.17.
The historical rank and industry rank for Abbisko Cayman's PS Ratio or its related term are showing as below:
FRA:8ZD'
s PS Ratio Range Over the Past 10 Years
Min: 5.31 Med: 25.38 Max: 153.75
Current: 10.07
During the past 7 years, Abbisko Cayman's highest PS Ratio was 153.75. The lowest was 5.31. And the median was 25.38.
FRA:8ZD's PS Ratio is ranked worse than 51.24% of 931
companies
in the Biotechnology industry
Industry Median: 9.55
vs FRA:8ZD: 10.07
During the past 7 years, Abbisko Cayman's highest 3-Year average Revenue per Share Growth Rate was 91.40% per year. The lowest was 91.40% per year. And the median was 91.40% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Abbisko Cayman PS Ratio Related Terms
Abbisko Cayman PS Ratio Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Abbisko Cayman's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's PS Ratio distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Abbisko Cayman's Share Price of today is €1.18.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Abbisko Cayman (FRA:8ZD) has a PS Ratio of 10.17 as of Aug. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Abbisko Cayman and its competitors. This is 60% below median its historical median of 25.38. Over the past decade, Abbisko Cayman's PS Ratio has ranged from 5.31 to 153.75. According to the industry distribution chart, Abbisko Cayman ranks #477 out of 931 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Abbisko Cayman's PS Ratio too high?
Abbisko Cayman's current PS Ratio of 10.17 is 60% below median its 10-year median of 25.38. Over the past 10 years, this metric has ranged from a low of 5.31 to a high of 153.75. The Biotechnology industry median PS Ratio is 9.55. Abbisko Cayman's value of 10.17 is 6.5% above this industry median. Based on the distribution chart, Abbisko Cayman ranks #477 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Abbisko Cayman has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #477 out of 931 companies for PS Ratio. This places Abbisko Cayman in the lower half of its industry. The industry median PS Ratio is 9.55. Abbisko Cayman's value of 10.17 is 6.5% above this benchmark. Historically, Abbisko Cayman's own PS Ratio has ranged from 5.31 to 153.75 over the past decade. While the company's 10-year median is 25.38 vs. the industry median of 9.55, Abbisko Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.55, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbisko Cayman's current PS Ratio of 10.17 is 6.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Abbisko Cayman and its competitors. For the Biotechnology industry, the median PS Ratio is 9.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbisko Cayman's current PS Ratio is 10.17, which is 60% below median its own 10-year median of 25.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (FRA:8ZD) is currently considered Fairly Valued. The stock's GF Value™ is €1.38, compared to a current price of €1.18 — trading 14.5% below its estimated fair value. The current PS Ratio is 10.17, which is 60% below median its 10-year median of 25.38 and 6.5% above the Biotechnology industry median of 9.55. Abbisko Cayman's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Abbisko Cayman (FRA:8ZD), the current PS Ratio is 10.17 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (FRA:8ZD) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of €1.18 is trading 14.5% below its estimated GF Value™ of €1.38.
GuruFocus considers Abbisko Cayman to be Fairly Valued.
Key valuation signals for FRA:8ZD:
PS Ratio: 10.17 (60% below median its 10-year median of 25.38)
GF Value™: €1.38 vs. price of €1.18 (14.5% below fair value)
Industry Position: 6.5% above the Biotechnology median (#477 of 931)
No single metric tells the full story. See the FRA:8ZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
55GF Score
Get the complete analysis for FRA:8ZD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8ZD has been successfully added to your 
